Waverly Advisors 13F: Adds $1.5M to AbbVie (ABBV) Stake

Waverly Advisors Increases Stake in AbbVie Inc.

Waverly Advisors lifted its investment in AbbVie Inc. (NYSE:ABBV) during the period, adding 5,800 shares to bring its total ownership to 224,676 shares. This change represents a 2.65% increase from the prior holding of 218,876 shares. The reported value of the stake reached about $56.8 million based on the filing data. This update comes from a Form 13F filed with the Securities and Exchange Commission, which captures holdings as of the reporting date and may not reflect current trades.

AbbVie Stock Valuation and Market Context

AbbVie shares trade around $252.59, sitting below the 50-day moving average of $255.68 while staying well above the 200-day moving average of $229.80. The healthcare giant carries a market value of roughly $467.4 billion and a trailing price-to-earnings ratio of 74.11. Future valuations look toward a forward price-to-earnings ratio of 16.26. The stock has traded between a 52-week low of $190.75 and a 52-week high of $267.47.

Recent Earnings and Dividend Profile

The drug manufacturer reported annual revenue of $64.39 billion alongside a revenue growth rate of 10.2%. Profitability metrics show a net margin of 9.80% and a return on equity. Investors receive an annual dividend rate of $6.92 per share, translating to a dividend yield of 2.62% with a payout ratio of 1.90. The company's next earnings report is scheduled for October 29, 2026.

Wall Street Analyst Updates

Several research firms updated their price targets and ratings for AbbVie through October 2026. On October 13, 2026, RBC Capital reiterated its outperform rating with a $280.00 price target. Earlier in the month, UBS maintained a neutral rating while lifting its target to $275.00 on October 9, 2026. Guggenheim kept a buy rating and a $288.00 target on October 9, 2026, while JP Morgan maintained an overweight rating with a target raised to $300.00 on October 8, 2026. Cantor Fitzgerald maintained an overweight rating with a $290.00 target on October 8, 2026. Morgan Stanley maintained an overweight rating with a target raised to $310.00 on October 7, 2026. Scotiabank maintained a sector outperform rating and raised its target to $320.00 on October 6, 2026. HSBC kept a buy rating with a $315.00 target on September 10, 2026. Overall, the stock holds a consensus buy recommendation and a mean price target of $278.61 across 28 analyst opinions.

Inside AbbVie's Biopharmaceutical Pipeline

AbbVie Inc. researches, develops, and sells pharmaceutical treatments across immunology, oncology, aesthetics, and neuroscience. Key therapies include Skyrizi and Rinvoq for autoimmune and inflammatory conditions, along with cancer treatments like Imbruvica and Venclexta. The company also markets facial injectables and botulinum toxin products under the Botox brand. Incorporated in 2012 and headquartered in North Chicago, Illinois, the enterprise employs roughly 57,000 workers worldwide.

Monitoring Future Portfolio Disclosures

Institutional investors continue to adjust their exposure to major pharmaceutical equities as market conditions shift. Prior filings from other wealth managers show mixed portfolio adjustments, such as recent trimming activity by Kmg Fiduciary Partners and Trexquant Investment. Observers will track upcoming SEC submissions to see if institutional interest in the healthcare sector broadens as the year concludes.